BMRN
Biomarin Pharmaceutical Inc
57.50$
+0.6%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Balance Sheet
Biomarin Pharmaceutical Inc (BMRN) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Total Assets" came in at 7,594 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 32 | 104 | 77 | 172 | 111 | 256 | 233 | 195 | 463 | 815 | 907 | 917 | 1,263 | 1,306 | 1,568 | 2,244 | 2,490 | 3,729 | 4,024 | 4,633 | 4,427 | 4,690 | 5,848 | 6,003 | 6,375 | 6,842 | 6,989 | 7,594 | |
| 13 | 66 | 45 | 137 | 81 | 225 | 85 | 69 | 334 | 644 | 738 | 468 | 504 | 470 | 743 | 1,137 | 1,426 | 1,090 | 1,422 | 2,207 | 2,056 | 1,942 | 2,342 | 2,274 | 2,751 | 2,956 | 3,232 | 3,953 | |
| 9.4 | 23 | 17 | 13 | 34 | 121 | 13 | 38 | 89 | 228 | 223 | 167 | 88 | 46 | 181 | 569 | 875 | 397 | 408 | 598 | 494 | 437 | 649 | 587 | 725 | 755 | 943 | 1,312 | |
| 9.4 | 63 | 40 | 131 | 74 | 206 | 49 | 48 | 289 | 586 | 560 | 301 | 274 | 195 | 451 | 785 | 945 | 593 | 790 | 1,396 | 1,084 | 754 | 1,065 | 1,014 | 1,292 | 1,074 | 1,138 | 1,561 | |
| 0.7 | 2.5 | 2.9 | 3.1 | – | – | 4.0 | 6.9 | 15 | 17 | 54 | 81 | 87 | 116 | 109 | 129 | 144 | 165 | 215 | 261 | 343 | 377 | 448 | 373 | 461 | 634 | 661 | 908 | |
| 0.1 | 0.7 | 0.4 | – | – | – | 2.3 | 11 | 25 | 32 | 73 | 79 | 110 | 130 | 129 | 163 | 199 | 272 | 355 | 476 | 531 | 680 | 699 | 777 | 894 | 1,107 | 1,233 | 1,299 | |
| – | – | 21 | 33 | 28 | 25 | 43 | 37 | 55 | 77 | 125 | 199 | 222 | 269 | 284 | 319 | 524 | 704 | 799 | 897 | 949 | 1,011 | 1,032 | 1,035 | 1,114 | – | – | – | |
| – | – | – | – | – | – | 45 | 21 | 21 | 21 | 21 | 24 | 53 | 52 | 52 | 54 | 54 | 197 | 197 | 197 | 197 | 197 | 196 | 196 | 196 | 196 | 196 | 196 | |
| 12 | 11 | 9.9 | – | – | – | 16 | 37 | 12 | 9.6 | 7.6 | 41 | 104 | 180 | 163 | 163 | 157 | 684 | 554 | 518 | 492 | 457 | 417 | 389 | 339 | 295 | 255 | 214 | |
| 2.1 | 5.2 | 6.9 | 12 | 12 | 138 | 301 | 273 | 346 | 628 | 630 | 595 | 545 | 533 | 553 | 903 | 963 | 1,329 | 1,257 | 1,824 | 1,459 | 1,568 | 1,742 | 1,733 | 1,772 | 1,890 | 1,331 | 1,507 | |
| 2.0 | 5.1 | 6.9 | 8.3 | 6.8 | 13 | 70 | 40 | 46 | 62 | 130 | 78 | 84 | 94 | 170 | 183 | 236 | 445 | 439 | 817 | 523 | 933 | 493 | 540 | 589 | 1,177 | 607 | 759 | |
| – | 0.0 | 0.0 | 1.6 | – | – | 43 | 11 | 6.8 | 6.3 | 141 | – | 76 | – | 23 | – | 643 | 662 | 22 | 361 | – | 373 | 12 | 10 | 10 | 503 | 23 | 8.7 | |
| 1.4 | 3.1 | 4.7 | 4.3 | 3.9 | 10 | 27 | 0.5 | 2.3 | 1.2 | 59 | 7.6 | 5.0 | 36 | 67 | 95 | 236 | 393 | 191 | 167 | 208 | 241 | 191 | 193 | 231 | 316 | 235 | 313 | |
| – | – | 0.1 | 4.0 | 3.4 | 126 | 228 | 213 | 292 | 564 | 497 | 497 | 378 | 348 | 325 | 656 | 658 | 662 | 661 | 814 | 830 | 486 | 1,075 | 1,079 | 1,083 | 593 | 595 | 597 | |
| 29 | 98 | 70 | 160 | 99 | 118 | -68 | -77 | 118 | 188 | 277 | 322 | 717 | 773 | 1,016 | 1,341 | 1,528 | 2,401 | 2,766 | 2,809 | 2,968 | 3,122 | 4,106 | 4,271 | 4,603 | 4,952 | 5,658 | 6,087 | |
| -15 | -43 | -81 | -148 | -226 | -301 | -489 | -563 | -592 | -607 | -577 | -577 | -371 | -425 | -539 | -716 | -850 | -1,022 | -1,521 | -1,638 | -1,694 | -1,721 | -862 | -926 | -789 | -622 | -195 | 154 | |
| 22 | 30 | 36 | 41 | 53 | 62 | 64 | 69 | 85 | 96 | 104 | 100 | 126 | 112 | 120 | 138 | 146 | 160 | 166 | 174 | 177 | 179 | 192 | 183 | 189 | 192 | 197 | 197 |
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.